Uncategorized

Amgen Seeks ‘Return to Growth’ for Tepezza as More Convenient Formulation Aces Phase 3

Published

4 hours ago

on

April 7, 2026

By

Temp User

Sales of Amgen’s thyroid eye disease drug Tepezza have slowed, dipping 1% to $457 million in the fourth quarter of 2025.

Related Topics:

Leave a Reply

Uncategorized9 years ago

These ’90s fashion trends are making a comeback in 2017
Contributors9 years ago

The final 6 ‘Game of Thrones’ episodes might feel like a full season
Uncategorized9 years ago

According to Dior Couture, this taboo fashion accessory is back
Uncategorized9 years ago

The old and New Edition cast comes together to perform
Uncategorized9 years ago

Phillies’ Aaron Altherr makes mind-boggling barehanded play
Uncategorized9 years ago

Uber and Lyft are finally available in all of New York State

Exit mobile version